Generates revenue from clinical and specialty laboratory testing, from manufacturing and selling pharmaceutical products, and from royalties, profit share and partner- and government-funded development of its drug and antibody programmes.
Geographic Exposure
United States71.85%
Chile10.28%
Ireland8.47%
Spain4.4%
Mexico4.21%
Other (rest of world)0.7%
Israel0.09%
Revenue Drivers
Clinical and specialty laboratory testing
Routine, esoteric and specialty diagnostic testing performed for healthcare providers and payers
CORE61%
Pharmaceutical product manufacturing and sales
Manufacturing, importing and selling prescription, generic and consumer health products
CORE25.9%
Drug licensing royalties and funded research
Royalties and profit share on partnered drugs plus funded antibody development contracts
SIGNIFICANT13.1%
End Markets
Healthcare insurers
Government payers and agencies
Physician offices, clinics and hospitals
Patients
Pharmaceutical licensing and commercialization partners
Employers and health plans
Specializations
MSTAR multispecific antibody platformSelf-assembling ferritin nanoparticle vaccine platformIn vivo CAR-T antibody-conjugated lipid nanoparticle technologyLong-acting oxyntomodulin, GLP-1 and parathyroid hormone analogsHigh-containment manufacturing of highly potent compoundsGovernment-funded antibody development against public health threats+1 more
Activities
Clinical laboratory testing
Pharmaceutical manufacturing
Drug research and development
Importation, distribution and marketing of pharmaceuticals
